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Word count: 3032 words
Abstract 
Objective: To establish whether synovial pathobiology improves current clinical classification 
and prognostic algorithms in early inflammatory arthritis and identify predictors of subsequent 
biologic therapy requirement.  
Methods: 200 treatment-naïve early-arthritis patients were classified as fulfilling RA1987 
ACR criteria (RA1987) or as undifferentiated arthritis (UA) and UA patients further classified 
into those fulfilling RA2010 ACR/EULAR criteria. Treatment requirements at 12 months 
(csDMARDs vs biologics vs no-csDMARDs treatment) was determined. Synovial tissue was 
retrieved by minimally-invasive, ultrasound-guided biopsy and underwent processing for 
immunohistochemical (IHC) and molecular characterisation. Samples were analysed for 
macrophage, plasma-cell and B- and T-cells markers, pathotype classification (lympho-
myeloid, diffuse-myeloid or pauciimmune) by IHC and  gene expression profiling by 
Nanostring. 
Results: 128/200 patients were classified as RA1987, 25 as RA2010 and 47 as UA. Patients 
classified as RA1987 criteria had significantly higher levels of disease activity, histological 
synovitis, degree of immune cell infiltration and differential upregulation of genes involved in 
B and T cell activation/function compared to RA2010 or UA, which shared similar clinical and 
pathobiological features. At 12 months follow up, a significantly higher proportion of patients 
classified as lympho-myeloid pathotype required biologic therapy. Performance of a clinical 
prediction model for biologic therapy requirement was improved by integration of synovial 
pathobiological markers from 78.8% to 89-90%. 
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Conclusion: The capacity to refine early clinical classification criteria through synovial 
pathobiological markers offers the potential to predict disease outcome and stratify 
therapeutic intervention to patients most in need. 
Keywords (5) Early Arthritis, Rheumatoid Arthritis Classification Criteria, Synovium 
pathotype, Ultrasound-guided biopsy. 
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INTRODUCTION 
The introduction of new classification criteria for Rheumatoid Arthritis (RA) in 2010 [1] has 
been demonstrated to be clinically useful with enhanced diagnostic sensitivity in early disease 
compared to 1987 criteria [2]; however, this is balanced by a lower specificity [3,4]. This is of 
particular importance, as data suggest that approximately 40% of patients with early 
inflammatory arthritis, not fulfilling 1987 criteria, may spontaneously remit whilst approx. 
30% will progress to RA [5]. Critically the mechanisms undelying the transition from 
undifferentiated arthritis (UA) to RA remain unknown though it has been suggested that 
qualitative or quantitative difference within synovial tissue may contribute to diverse disease 
evolution and/or treatment response [6,7]. Thus, pre-treatment stratification of early 
inflammatory arthritis is important in order to target therapy to poor prognosis patients. 
Previous data suggest that stratifying early arthritis according to RA2010 vs RA1987 
classification criteria reveals significant clinical heterogeneity in diagnosis at 2 year follow up 
[8] although subsequent analysis of synovial tissue did not suggest that such clinical 
heterogeneity translated to significant differences in synovial pathobiology [9]. However, 
recently published data from a cohort of 144 early RA patients has demonstrated that synovial 
cellular and molecular signatures define prognostic and treatment response phenotypes [10]. 
Importantly whether clinical heterogeneity associated with the introduction of the 2010 
ACR/EULAR criteria can be explained by synovial pathobiological signatures and whether 
they associate with subsequent disease outcome, up to now, remains unk own. 
Therefore, the aim of this study was to investigate whether in patients with early inflammatory 
arthritis synovial cellular and molecular signatures: (i) segregate according to clinical 
classification (RA1987 vs RA2010 vs UA)  (ii) change depending on symptom duration and, 
(iii) determine prognosis including subsequent requirement for biologic therapy. 
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PATIENTS AND METHODS 
Patients
200 consecutive inflammatory arthritis patients recruited at Barts Health NHS Trust as part of 
the multi-centre pathobiology of early arthritis cohort (http://www.peac-mrc.mds.qmul.ac.uk) 
were included within the study. Patients were treatment naïve (csDMARD and steroid) and had 
<1 year symptoms.   
At baseline patients underwent collection of routine demographic data and were categorised 
according to the following criteria: (i) RA1987 [2] or (ii) UA. 2010 ACR/EULAR criteria for 
RA [1] were then applied to further classify patients with UA, resulting in three groups: (i) 
RA1987 (RA1987+/RA2010+), (ii) RA2010 (RA1987-/RA2010+) and (iii) UA (RA1987-
/RA2010-). An ultrasound (US) guided synovial biopsy of a clinically active joint was 
performed [11]. Patients were then commenced on standard conventional synthetic 
(cs)DMARD therapy with a treat-to-target approach to treatment escalation (DAS28<3.2). 
Patients failing csDMARD therapy were commenced on biologic therapy (anti-TNF, 
Tocilizumab or Rituximab) according to the prevailing UK National Institute for Clinical 
Excellence (NICE) prescribing algorithm if they continued to have a DAS28>5.1 following 6 
months of therapy [12]. At 12 months follow-up patients w re categorised as follows: i. self-
limiting (SL) disease (DAS28<3.2 and off csDMARD/steroid therapy) vs persistent disease 
(PD) (DAS28>3.2 and/or csDMARD) and ii. Symptomatic treatment (non-steroidal anti-
inflammatories) treatment vs csDMARD therapy vs Biologic+/-csDMARD therapy.
Synovial biopsy collection and processing
A minimum of 6 biopsies per patient were collected for paraffin embedding and if intact lining 
layer identified underwent histopathological assessment. Synovitis score was determined using 
a previously validated scoring system [13]. Following immunohistochemical staining of 
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sequentially cut slides using previously reported protocols for B cells (CD20), T cells (CD3), 
macrophages (CD68) and plasma cells (CD138) the degree of immune cell infiltration was 
assessed semi-quantitatively (0-4) [14]. Biopsies were stratified into 1 of 3 synovial pathotypes 
according to the following criteria: i) Lympho-myeloid presence of grade 2-3 
CD20+aggregates, (CD20≥2) and/or CD138>2 ii) diffuse-myeloid CD68 SL≥ 2, CD20≤1 
and/or CD3≥1, CD138≤2 and iii) pauciimmune CD68 SL<2 and CD3, CD20, CD138<1
Nanostring analysis
A minimum of 6 synovial samples per patient were immediately immersed in RNA-Later and 
RNA extraction performed as previously described [10]. RNA samples then underwent 
profiling for expression of 238 genes preselected based on previous microarray analyses of 
synovial tissue from patients with established RA [15] and/or relevance to RA pathogenesis.  
Raw NanoString counts were processed using the NanoStringQCPro package in R 
3.2.0.  Counts were normalised for RNA content by global gene count normalisation and then 
log transformed (base 2).  The validity of normalisation was then checked via box- and scatter 
plots of normalised counts. Benjamini-Hochberg method was used to adjust for multiple 
testing, and genes were considered to be differentially expressed if they demonstrated an FDR-
adjusted p-value <0.01.
Statistical analysis
Statistical analyses were run using R.3.0.2. For three way comparisons, Kruskal-Wallis test 
was used for continuous and Chi-squared or Fisher’s exact test used for categorical variables 
as appropriate. A p-value <0.05 was considered statistically significant. Post hoc comparison 
tests were performed using Dunn test or Bonferroni correction as appropriate.
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Linear regression models: Logistic regression using forward, backward and bidirectional 
stepwise selection was employed using the glm function in R.
Gene expression predictors were selected by L1 (LASSO) sparse logistic regression using R 
package glmnet. The penalty parameter λ was optimised using 10-fold cross-validation. λ 
corresponding to the minimum mean cross-validated error was retained as final penalty 
parameter in the model. 
Predictive performance evaluation:  Predictive performance of the final prediction model was 
assessed by computing the area under the receiver operating characteristic curve (AUC), using 
both apparent and internal validation with 95% CI. Internal validation using a bootstrap method 
[16,17] (performed with R package boot version 1.3-18) was employed to correct for over-
fitting, to generate unbiased optimism-adjusted estimates of the C statistic (AUC) with low 
absolute error. Bootstrap estimate of the AUC statistic was computed by random sampling with 
replacement 500 times to enable estimation f the optimism corrected AUC. 
RESULTS 
Patient demographics and clinical correlations 
200 PEAC patients were included, 128/200 (64%) patients were classified as RA1987 (RA 
1987+/RA2010+) and 72/200 (36%) as UA.  Of the UA patients, 25 were further classified as 
RA2010 (RA1987-/RA2010+) (25/200, 12.5%) and 47 remained as UA (RA1987-/RA2010-) 
(47/200, 23.5%) (Figure 1A). No significant difference in mean age, disease duration or ESR 
between groups was demonstrated. However, the RA1987 group had significantly higher levels 
of CRP, TJC, SJC, DAS28, RF, ACPA and VAS and significantly higher numbers of patients 
sero positive for RF and ACPA compared to either the RA2010 or UA groups (Figure 1B). SJC 
and ACPA titre were the only clinical parameters with significant differences between the 
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RA2010 and UA groups, indicating that in terms of clinical measures of disease activity these 
two groups are relatively homogenous. 
Synovial pathotypes distinguish clinical phenotypes regardless of disease duration
Synovial biopsies were obtained predominantly from small joints (81.5%) (Figure 2A). 
Patients with synovial tissue suitable for histological analysis (166/200) were segregated 
according to baseline synovial pathotype (Figure 2B) and differences in clinical parameters 
evaluated. We demonstrated significantly higher mean DAS28 within the lympho-myeloid 
compared to either the diffuse-myeloid or pauciimmune group (5.82 vs 4.93 vs 4.86, p<0.001). 
Mean CRP was significantly higher in the lympho-myeloid and diffuse-myeloid vs 
pauciimmune groups (16.86 vs 15.52 vs 9.55, p<0.001) and a significantly higher number of 
patients were sero-positive for either RF (p=0.012) or ACPA (p=0.011) within the lympho-
myeloid group (Figure 2C).  To evaluate whether disease duration influenced prevalence of 
synovial pathotype, patients were stratified into four groups according to disease duration at 
baseline (1-3m, 4-6m, 7-9m and 10-12m) and frequency of synovial pathotype determined. No 
significant differences in synovial pathotype frequency at each time point was demonstrated 
(p=0.65) (Figure 2D). 
RA1987 patients display significantly higher levels of synovial immune cell infiltration 
compared to RA2010 and UA patients
Patients were segregated according to pathotype and further into RA1987, RA2010 and UA 
categories. A higher proportion of patients within the RA1987 group were categorised as 
lympho-myeloid (vs diffuse-myeloid or pauciimmune) (43.5% vs 33% vs 23.5%) (Figure 3A). 
We also demonstrated a significantly higher mean synovitis, CD3+ T cell, CD20 +B cell, 
CD138+ plasma cell and CD68+ SL/L macrophage score between the RA1987 group and both 
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the RA2010 and UA groups (p<0.001) (Figure 3B). We saw no significant differences in 
synovitis score, mean CD3+T, CD20+B, CD68+ L or SL macrophage or CD138+ plasma cell 
number between the RA2010 and UA group (Figure 3B), indicating that these two groups are 
relatively homogenous in terms of tissue pathology. 
Synovial genes regulating B cell activation and function are significantly upregulated in 
RA1987 patients compared to the RA2010/UA groups. 
145/200 patients had RNA available for nanostring analysis (95/128 RA1987, 12/25 RA2010 
and 38/47 UA patients) and were analysed for differential gene expression (238 genes) between 
groups.
Comparing RA1987 vs RA2010 groups we demonstrated a significant differential expression 
of 53 genes (Figure 3C).  In line with the histological analysis a number of differentially 
upregulated genes within the RA1987 cohort were involved in mediating B cell 
activation/function (e.g. CD79A, CD38, IGJ, CXCL13, IRF4, CCL19, CD38, TNFA, and IL6). 
When evaluating gene expression between RA1987 and UA groups we found a similar trend 
with differential upregulation of a number of genes within the RA1987 cohort mediating B cell 
activation/function although only CXCL13 remained significant following correction for 
multiple comparisons (Figure 3D).  Conversely when evaluating gene expression between the 
RA2010 and UA cohorts only 7 genes appeared as significant with a preponderance of 
differentially upregulated genes within the RA2010 cohort mediating cartilage biology 
(COMP, DKK3, INHBA) and none remaining significant after correction for multiple 
comparisons (Figure 3E). 
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Classification as RA1987 criteria at disease onset predicts persistent disease at 12 months  
190/200 patients had 12 month follow up data available, we examined whether baseline 
synovial pathotype was associated with disease evolution. 119/121 (99%) RA1987 patients and 
19/22 (90%) RA2010 had PD (Figure 4A). Within the UA cohort 11/47 (23%) had other 
diagnoses. Of the remaining 36 patients, 26/36 (72.2%) had PD, and 10/36 (27.8%) SL. Of the 
UA patients with PD 4/26 (15.3%) progressed to fulfil 2010ACR/EULAR criteria RA at 12 
months. Results demonstrated a significantly higher proportion of patients with SL disease in 
the UA group compared to the RA2010 or RA1987 groups and a significantly higher number 
of patients within the RA1987 group with PD (Figure 4B). When evaluating the effect of 
baseline pathotype we demons rated a higher proportion of patients with a lympho-myeloid vs 
diffuse-myeloid or pauciimune pathotype (39% vs 32% vs 13%) with PD and a higher number 
of patients with a diffuse-myeloid vs lympho-myeloid or pauciimmune pathotype (54% vs 18% 
vs 27%) with SL (Figure 4C). 
A baseline lympho-myeloid pathotype significantly associates with 12 month requirement 
for biologic therapy. 
Patients stratified according to diagnostic group or pathotype were further classified according 
to 12 month treatment requirement: i. symptomatic treatment, ii. csDMARDs or iii. 
biologics+/-csDMARDs. A significantly higher proportion of RA1987 patients required 
biologic compared with RA2010 and UA (27.82% vs 20.83% vs 10.63%) (p<0.001) (Figure 
5A) and importantly, lympho-myeloid (vs diffuse-myeloid or pauciimmune) pathotype 
significantly associated with 12 month requirement for biologic therapy (57% vs 21% vs 21% 
p=0.02) (Figure 5B). 
We then compared expression of the 238 genes in the Nanostring panel between patients 
requiring biologic therapy (n=34) or not (n=106) and found 119 differentially expressed genes. 
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Patients requiring biologic therapy had significantly higher differential upregulation of genes 
regulating B and T cell proliferation, differentiation and activation (e.g. TNFRSF13C, CD79A, 
CD2, CD3E and CD38), genes involved in matrix metallopeptidase production/regulation (e.g. 
MMP1 and TIMP1), genes involved in cytokine mediated cellular activation (TNFA, 
TRAF3IP3, IFNA1), and osteoclastogenesis inhibition (DEF6). Patients who did not require 
biologic therapy expressed some B and T cell regulation genes and B proliferation markers but 
mostly markers of fibroblast proliferation and cartilage turnover (Figure 5C). 
To determine whether disease duration influenced outcome we segregated patients according 
to 12 month treatment (biologic therapy or not) and further into disease duration quartiles 
(Figure 5D) and demonstrated no significant differences in terms of disease duration at 
diagnosis. Next, we segregated patients treated with biologic therapy (n=39) according to 
quartiles of disease duration and then synovial pathotype.  We found no significant differences 
in patient number in each quartile (P=0.3) (Figure 5E). These results strongly suggest that 
synovial pathotype rather than disease duration influences 12 month treatment outcome. 
Synovial gene expression signatures enhance the performance of clinical prediction 
models for biologic requirement 
To determine whether baseline clinical and gene expression data could be combined into a 
model for predicting requirement for biologic therapy, we used 2 complementary approaches: 
a logistic regression model to identify predictive clinical covariates, and a penalized method 
based on logistic regression with an L1 regularisation penalty (LASSO) to identify genes 
improving the clinical model. 
9 baseline clinical covariates were considered as candidates in the regression model: disease 
duration, ESR, CRP, RF, ACPA, TJC, SJC, DAS28, and pathotype (two categories, lympho-
myeloid vs pauciimmune/diffuse-myeloid). Logistic regression models using backward 
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forward and bidirectional stepwise selection resulted in selection of the same set of clinical 
covariates: DAS28, pathotype, CRP and TJC. The apparent predictive performance of the 
model evaluated by AUC was 0.78 (95% CI=0.70-0.87).
Genes were selected to improve the clinical model using logistic regression with an L1 
regularization penalty (LASSO) applied on the 4 clinical covariates selected by the previous 
logistic regression and the 119 genes identified as being significantly differentially expressed 
between the biologic and non-biologic groups. Models in which clinical predictors were 
penalised or subject to forced inclusion were compared. When all predictors were penalised, 
11 predictors were retained in the final model and when the clinical covariates were not 
penalised, 13 predictors were retained (Figure 6A). In both the penalised and unpenalized 
clinical model the apparent prediction performance was improved (apparent AUC=0.89, 95% 
CI=0.83-0.95 and AUC=0.90, 95% CI=0.84-0.95) (Figure 6B). We additionally performed 
internal validation to correct the AUC performance measure for over-fitting by calculating the 
optimism of the AUC for each model by boot-strapped sampling with replacement from the 
original dataset. The optimism corrected AUC was 0.75 for the pure clinical model and 0.81 
for the clinical and gene model (LASSO) (Figure 6C and 6D) suggesting that including both 
clinical covariates and genes in the model results in an improvement of the predictive ability 
of the model. 
DISCUSSION 
These results present a number of novel findings: firstly they strongly suggest that early 
inflammatory arthritis patients not fulfilling RA1987 criteria display similar clinical, synovial 
histological and molecular features irrespective of further classification according to RA2010 
or UA criteria. Secondly these data also suggest that a lympho-myeloid pathotype at disease 
onset predicts poor outcome with patients subsequently requiring biologic therapy irrespective 
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of clinical classification, and finally that integration of histological and molecular signatures 
into a clinical prediction model enhances sensitivity/specificity for predicting whether patients 
will require biologic therapy. 
To the best of our knowledge these results emerge from the largest synovial tissue treatment-
naïve early arthritis cohort reported to date and support previous data from early RA cohorts 
suggesting that a synovial immune cell infiltrate characterised by a predominant infiltrate of B 
cells associates with more active disease [18] and sero-positivity for RF and ACPA [10]. The 
results suggest that this effect also extends to patients within the UA cohort. The clinical 
similarities between RA2010+/RA1987- patients and those with UA has been reported 
previously [8] and the data presented herein provides a pathophysiological explanation for this 
with the demonstration of homogeneous synovial cellular and molecular signatures among the 
two groups.  The data show a lower percentage of patients requiring biologic therapy in 
RA2010+/RA1987- group, in line with the expectation that the ACR/EULAR 2010 criteria 
enable an earlier diagnosis and thus efficacious treatment. However, it is also possible that this 
group has a milder pathology from the beginning. 
Although synovial pathotypes per se do not appear to distinguish between patients at risk of 
developing PD rather than SL disease, this is not surprising given the early and treat-to-target 
approach pursued in the study rather than observing untreated natural disease evolution. 
However when applying 12 month biologic requirement as a prognostic outcome we 
demonstrated that patients with a lympho-myeloid pathotype with a dense synovial infiltrate 
enriched in B cells and significant upregulation of T/B cell genes at disease onset predicted 
requirement for subsequent biologic therapy and critically that this was independent of disease 
duration. These results are consistent with recently published data in early RA which reports 
that the lympho-myeloid pathotype is associated with highly agressive disease and worse 
radiographic outcomes [10]. The current study reinforces these findings demonstrating that, at 
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12-months follow-up, a significantly higher proportion of patients classified as lympho-
myeloid pathotype required biologic therapy. The study also calls into question the current 
dogma surrounding “an early window of opportunity” for all patients with RA [19–21], 
suggesting that pathotype rather than simply disease duration influences outcome and that 
intensive therapeutic regimens should be targeted to poor prognostic pathotypes.  This notion 
is supported by the demonstration that the integration of synovial histological and molecular 
markers into a clinical prediction model for biologics use improves sensitivity/specificity from 
78.8% to 89-90% independently from disease duration.
Discrepancy with previously reported data suggesting that synovial heterogeneity does not 
relate to clinical phenotypes [9], maybe explained by the fact that in our study the majority of 
biopsies were performed on small joints while in that cohort arthroscopic biopsy was restricted 
to patients with mainly large joint involvement and, thus, a potential selection bias [22]. 
Additionally, the paired histological and molecular data in the largest biopsy-driven early 
arthritis cohort reported to date ensured internal validation and high classification accuracy. 
Our study does have limitations however, for example the real-life nature of the study did not 
permit the true evaluation of the natural history of the disease or outcome, as no patients were 
left untreated and therapy was not actively withdrawn. Also a treat to target approach, treatment 
escalation and initiation of biologic therapy was determined by treating physicians according 
to NICE guidelines rather than study protocol. 
Within these limitations, our results are robust and suggest that the introduction of the new 
RA2010 classification criteria brings additional clinical and biological heterogeneity into early 
patient classification compared to the 1987 criteria with limited ability of RA2010 criteria alone 
to predict poor outcome. The demonstration that the integration of synovial pathobiological 
markers into clinical algorithms predicting poor outcome (requirement for biologic therapy) 
independent of disease duration suggests that the “window of opportunity” is wider than 6 
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months and early stratification of biologic therapies according to poor prognostic synovial 
pathobiological subtypes at disease onset may improve the outcome of these patients. 
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Figure Legends
Figure 1. Baseline Patient Demographics. 
A. Baseline classification of patients. 200 patients were classified into RA1987 vs 
undifferentiated arthritis (UA). RA 2010 ACR/EULAR Criteria was then applied to UA 
patients. Final 3 groups obtained showed 47 patients UA (RA 1987-/RA2010-), RA 
2010 (RA1987-/RA2010+), RA 1987 (RA1987+/RA2010+). 
B. Demographics according to classification criteria. Data are presented as mean (SD, 
standard deviation) for continue variables and frequency and percentages for 
categorical variables. Baseline characteristics between the 3 groups were compared 
using Kruskal-Wallis or Fisher’s exact test as appropriate. For post hoc comparison, 
Dunn tests were run and p-value from pairwise comparison reported in the last 3 
columns of the table. ESR: Erythrocyte sedimentation rate ; CRP: C-reactive protein; 
28TJC: 28 tender joint count; 28SJC: 28 swollen joint count; DAS28: Disease Activity 
Score 28 joints; RF titre: Rheumatoid factor titre (IU/ml); ACPA Titre: Anti-
citrullinated protein antibody titre (IU/L); RF + e: rheumatoid factor serum positive 
(>15IU/L); ACPA +ve: Anti-citrullinated protein antibody (>20IU/L).
Figure 2. Patient demographics and disease activity: comparison between pathotypes. 
A. Number of biopsy procedures per joint  MCP (Metacarpophalangeal), MTP 
(Metatarsophalangeal), PIP (Proximal Inter phalangeal). 
B. Representative images of synovial pathotypes. H&E: Haematoxylin & Eosin. 
Sections underwent immunohistochemical staining and semi-quantitative scoring (0-4) 
to determine the degree of CD20+ B cells, CD3+ T cells, CD68+ lining (l) and sublining 
(sl) macrophage and CD138+ plasma cell infiltration. Sections were categorised into 
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three pathotypes: (i) Pauci-iumne (CD68 SL<2 and or CD3, CD20, CD138<1), (ii) 
Diffuse-Myeloid: (CD68SL>2, CD20<1 and or CD3>1) and (iii) Lympho-Myeloid: 
(grade 2-3 CD20+ aggregates, CD20>2). Arrow heads  indicate positive stain cells. 
Empty arrows indicate B cell aggregates.
C. Demographic Analysis by Pathotype. Data are presented as mean and standard 
deviation (SD) for numerical variables and frequency and percentage for categorical 
variables. Baseline characteristics between the 3 pathotypes were compared using a 
Kruskall-Wallis test and Fisher-test (RF and ACPA positivity) as appropriate. Post hoc 
analysis for significant differences using Dunn test for multiple comparison. A P-value 
of <0.05 was considered statistically significant. 
D. Pathotype according to disease duration (months) at diagnosis. Absolute values (N) 
and percentage. A P-value of <0.05 was considered statistically significant. 
Figure 3. Variation in synovial pathobiology according to clinical classification of 
patients. 
A. Baseline clinical classification compared with pathotype. Baseline subgroups (RA 
1987, RA2010 and UA) were compared with pathotype. Fisher test used for analysis. 
B. Immune cell infiltration for each clinical subgroup. Kruskal-Wallis test for 
comparison between 3 groups. Post hoc analysis for significant differences using Dunn 
test for multiple comparison.
C. (C-E) Gene expression analysis for comparison between subgroups. T-test for 
comparison and Volcano plot for representative image. Positive values represent 
upregulation and negative values downregulation. Green circles above green horizontal 
line represents non-corrected for multiple analysis expressed genes between groups. 
Red circles above red line represents corrected p-values (Benjamini-Hochberg method) 
Page 21 of 59
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
21
for multiple analysis. (C) Volcano plot RA 1987 vs RA 2010: Difference in gene 
expression between patient fulfilling RA 1987 ACR criteria and RA 2010 
ACR/EULAR Criteria. (D) Volcano plot RA 1987 vs UA: Difference in gene 
expression between patient fulfilling RA 1987 ACR criteria and Undifferentiated 
Arthritis. (E) Volcano plot RA 2010 vs UA: differences in gene expression between 
patient fulfilling RA 2010 ACR/EULAR criteria and UA.  
Figure 4. Disease evolution. 
A. Patient classification after 12 months follow up. Disease outcome after 12 months 
of follow up for each of the initial baseline subgroups (RA1987/RA2010/UA). 
Disease evolution classified as self-limiting or persistent disease. Other diagnosis as 
described for those who were re-classified after 1 year form UA cohort. 
B. Disease evolution by subgroups. Disease evolution was compared with Baseline 
subgroups (RA 1987, RA2010 and UA). Fisher test used for analysis. 
C. Disease evolution by pathotype. Disease evolution was compared with pathotype 
(Pauci-imune vs Diffuse-Myeloid vs Lympho-Myeloid. Fisher test used for analysis. 
A P-value of <0.05 was considered statistically significant. 
Figure 5. 
A. Comparison between diagnostic subgroups and treatment outcome at 12month 
follow up. Treatment required was divided in 3 groups: (i) No treatment; (ii) 
csDMARDs only,  (iii) csDMARDs +/- Biologics. Fisher test for analysis. 
B. Comparison between pathotype and treatment outcome at 12 months. 
C. Gene expression analysis, represented in a Volcano plot comparison between patient 
requiring Biologics vs non-biologic group. T-test comparison for gene difference 
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expression between groups. Positive values represents upregulation and negative values 
downregulation. An adjusted (Benjamini-Hochberg correction for multiple analysis) P-
value of <0.01 was considered statistically significant, represented as dots above red 
line. Green dots above green line for gene expression significance when no correction 
applied for multiple analysis (P value <0.05). D. Treatment outcome according to 
baseline disease duration. Fisher test for analysis. E. Pathotype according to 
baseline disease duration for Biologic patient cohort. Fisher test for analysis. A P-
value of <0.05 was considered statistically significant unless otherwise stated.
Figure 6. Prediction model. 
A-B Identification of clinical and gene expression features predictive of biologic 
therapy use at 1 year. Logistic regression, coupled with backward and stepwise model 
selection was applied to baseline clinical parameters against a dependent variable of 
Biologic therapy use or not at 12 months to select which clinical covariate contributed 
the most to the prediction. Selected covariates (119 genes+4 clinical covariates) were 
entered simultaneously into a logistic model with an L1 regularization penalty 
(LASSO) in order to determine the optimal sparse prediction model. A similar 
predictive performance of the model when clinical was seen when results were 
penalized (blue dashed line, figure 6A) than when they were not penalized (red dotted 
line, figure 6A) with a slightly different set of selected covariates (Figure 6B). Figure 
6B shows the non-zero weights associated with the final variables selected by the 
LASSO regression. The grey spaces represent the variables that were not selected by 
the model.
C-D Lambda training curve from the final glmnet fitted model. The red dots
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represent mean binomial deviance using 10-fold cross-validation. The error bars 
represent standard error of binomial deviance. The vertical dotted lines indicate 
minimum binomial deviance (λmin) and a more regularized model for which the 
binomial deviance error is within one standard error of the minimum binomial deviance 
(λ1se). λmin was selected, corresponding to 11 non-zero coefficients in the final model 
for the LASSO where clinical were penalized (Figure 6C) and 13 non-zero coefficients 
in the final model for the LASSO where clinical were not penalized (Figure 6D).
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Key messages: 
What is already known about this subject?
The introduction of ACR/EULAR RA classification criteria have impacted positively on early 
diagnosis and treatment RA leading to better outcomes.  By the same token, broader criteria 
have led to the inclusion of patients with milder and more heterogenous disease. This, together 
with the inability to precisely predict disease prognosis and treatment response at the individual 
patent levels, emphasise the need to identify patients at risk of accelerated structural damage 
progression and fast-track aggressive/biologic therapies to patients with poor prognosis. 
What does this study add?
This study analyses the largest biopsy-driven early inflammatory arthritis cohort to date (200 
patients) and, through a detailed synovial cellular and molecular characterization refines 
ACR/EULAR disease classification. In addition, the study identifies synovial pathobiological 
markers associated with with the lympho-myeloid pathotype and the requirement of biologic 
therapy at 12 months, reinforcing recently published data th  indicates that these patients are 
affected by highly agressive disease and worse radiographic outcome. Notably, these findings 
are independent from the time of diagnosis within the first 12 months of symptoms initiation, 
suggesting that the so called “window of opportunity” is wider than 6 months and early 
stratification of biologic therapies according to poor prognostic synovial pathobiological 
subtypes at disease onset may improve the outcome of these patients. The integration of 
synovial pathobiological markers into a logistic regression model improves the prediction 
accuracy from 78.8% (clinical) to 89-90% (clinical +  molecular) and enables the identification 
at disease onset of patients who subsequently require biologic therapy. Thus, this study 
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provides support to the notion that biologic therapies should be started early in patients with 
poor prognosis.  
How might this impact on clinical practice or future developments?
The identification at disease onset of patients who are unlikely to respond to csDMARDs, 
remains a major unmet need. The capacity to refine early clinical classification criteria through 
application of synovial pathobiological markers and the ability to identify patients who 
subsequently require biologic therapy at disease onset offers the opportunity to stratify 
therapeutic intervention to the patients most in need. This present study adds weight to the need 
to change current therapeutic algorithms and start biologic therapies at disease onset in patients 
with poor prognosis.  This is likely to have a major impact on disease control/remission and 
long-term disability, as notionally supported by numerous early intervention studies using 
biologic therapies. 
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Synovial tissue signatures enhance clinical classification and prognostic/treatment 
response algorithms in early inflammatory arthritis and predict requirement for 
subsequent biologic therapy: results from the Pathobiology of Early Arthritis Cohort 
(PEAC)
Running Title / Short Title: Synovial tissue signatures enhance clinical classification and 
prognostic/treatment response  prediction in early arthritis
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Abstract 
Objective: To establish whether synovial pathobiology improves current clinical classification 
and prognostic algorithms in early inflammatory arthritis and identify predictors of subsequent 
biologic therapy requirement.  
Methods: 200 treatment-naïve early-arthritis patients were classified as fulfilling RA1987 
ACR criteria (RA1987) or as undifferentiated arthritis (UA) and UA patients further classified 
into those fulfilling RA2010 ACR/EULAR criteria. Treatment requirements at 12 months 
(csDMARDs vs biologics vs no-csDMARDs treatment) was determined. Synovial tissue was 
retrieved by minimally-invasive, ultrasound-guided biopsy and underwent processing for 
immunohistochemical (IHC) and molecular characterisation. Samples were analysed for 
macrophage, plasma-cell and B- and T-cells markers, pathotype classification (lympho-
myeloid, diffuse-myeloid or pauciimmune) by IHC and  gene expression profiling by 
Nanostring. 
Results: 128/200 patients were classified as RA1987, 25 as RA2010 and 47 as UA. Patients 
classified as RA1987 criteria had significantly higher levels of disease activity, histological 
synovitis, degree of immune cell infiltration and differential upregulation of genes involved in 
B and T cell activation/function compared to RA2010 or UA, which shared similar clinical and 
pathobiological features. At 12 months follow up, a significantly higher proportion of patients 
classified as lympho-myeloid pathotype required biologic therapy. Performance of a clinical 
prediction model for biologic therapy requirement was improved by integration of synovial 
pathobiological markers from 78.8% to 89-90%. 
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Conclusion: The capacity to refine early clinical classification criteria through synovial 
pathobiological markers offers the potential to predict disease outcome and stratify 
therapeutic intervention to patients most in need. 
Keywords (5) Early Arthritis, Rheumatoid Arthritis Classification Criteria, Synovium 
pathotype, Ultrasound-guided biopsy. 
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INTRODUCTION 
The introduction of new classification criteria for Rheumatoid Arthritis (RA) in 2010 [1] has 
been demonstrated to be clinically useful with enhanced diagnostic sensitivity in early disease 
compared to 1987 criteria [2]; however, this is balanced by a lower specificity [3,4]. This is of 
particular importance, as data suggest that approximately 40% of patients with early 
inflammatory arthritis, not fulfilling 1987 criteria, may spontaneously remit whilst approx. 
30% will progress to RA [5]. Critically the mechanisms undelying the transition from 
undifferentiated arthritis (UA) to RA remain unknown though it has been suggested that 
qualitative or quantitative difference within synovial tissue may contribute to diverse disease 
evolution and/or treatment response [6,7]. Thus, pre-treatment stratification of early 
inflammatory arthritis is important in order to target therapy to poor prognosis patients. 
Previous data suggest that stratifying early arthritis according to RA2010 vs RA1987 
classification criteria reveals significant clinical heterogeneity in diagnosis at 2 year follow up 
[8] although subsequent analysis of synovial tissue did not suggest that such clinical 
heterogeneity translated to significant differences in synovial pathobiology [9]. However, 
recently published data from a cohort of 144 early RA patients has demonstrated that synovial 
cellular and molecular signatures define prognostic and treatment response phenotypes [10]. 
Importantly whether clinical heterogeneity associated with the introduction of the 2010 
ACR/EULAR criteria can be explained by synovial pathobiological signatures and whether 
they associate with subsequent disease outcome, up to now, remains unknown. 
Therefore, the aim of this study was to investigate whether in patients with early inflammatory 
arthritis synovial cellular and molecular signatures: (i) segregate according to clinical 
classification (RA1987 vs RA2010 vs UA)  (ii) change depending on symptom duration and, 
(iii) determine prognosis including subsequent requirement for biologic therapy. 
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5
PATIENTS AND METHODS 
Patients
200 consecutive patients with inflammatory arthritis patients recruited at Barts Health NHS 
Trust as part of the multi-centre pathobiology of early arthritis cohort (http://www.peac-
mrc.mds.qmul.ac.uk) were included within the study. PAll patients were treatment naïve 
(csDMARD and steroid) and had <1 year symptoms.   
At baseline patients underwent collection of routine demographic data and were categorised 
according to the following criteria: (i) RA1987 [2] or (ii) UA. 2010 ACR/EULAR criteria for 
RA [1] were then applied to further classify patients with UA, resulting in three final groups: 
(i) RA1987 (RA1987+/RA2010+), (ii) RA2010 (RA1987-/RA2010+) and (iii) UA (RA1987-
/RA2010-). An ultrasound (US) guided synovial biopsy of a clinically active joint was then 
performed [11]. Patients were then commenced on standard conventional synthetic 
(cs)DMARD therapy with a treat-to-target approach to treatment escalation (DAS28<3.2). 
Patients failing csDMARD therapy were commenced on biologic therapy (anti-TNF, 
Tocilizumab or Rituximab) according to the prevailing UK National Institute for Clinical 
Excellence (NICE) prescribing algorithm if they continued to have a DAS28>5.1 following 6 
months of therapy [12]. At 12 months follow-up patients were categorised asaccording to the 
followsing: i. self-limiting (SL) disease (DAS28<3.2 and off csDMARD/steroid therapy) vs 
persistent disease (PD) (DAS28>3.2 and/or csDMARD) and ii. Symptomatic treatment (non-
steroidal anti-inflammatories) treatment vs csDMARD therapy vs Biologic+/-csDMARD 
therapy.
Synovial biopsy collection and processing
A minimum of 6 biopsies per patient were collected for paraffin embedding and if intact lining 
layer identified underwent histopathological assessment. Synovitis score was determined using 
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a previously validated scoring system [13]. Following immunohistochemical staining of 
sequentially cut slides using previously reported protocols for B cells (CD20), T cells (CD3), 
macrophages (CD68) and plasma cells (CD138) the degree of immune cell infiltration was 
assessed semi-quantitatively (0-4) [14]. Biopsies were then stratified into 1 of 3 synovial 
pathotypes according to the following criteria: i) Lympho-myeloid presence of grade 2-3 
CD20+aggregates, (CD20≥2) and/or CD138>2 ii) diffuse-myeloid CD68 SL≥ 2, CD20≤1 
and/or CD3≥1, CD138≤2 and iii) pauciimmune CD68 SL<2 and CD3, CD20, CD138<1
Nanostring analysis
A minimum of 6 synovial samples per patient were immediately immersed in RNA-Later and 
RNA extraction performed as previously described [10]. RNA samples then underwent 
profiling for expression of 238 genes preselected based on previous microarray analyses of 
synovial tissue from patients with established RA [15] and/or relevance to RA pathogenesis.  
Raw NanoString counts were processed using the NanoStringQCPro package in R 
3.2.0.  Counts were normalised for RNA content by global gene count normalisation and then 
log transformed (base 2).  The validity of normalisation was then checked via box- and scatter 
plots of normalised counts. Benjamini-Hochberg method was used to adjust for multiple 
testing, and genes were considered to be differentially expressed if they demonstrated an FDR-
adjusted p-value <0.01.
Statistical analysis
Statistical analyses were run using R.3.0.2. For three way comparisons, Kruskal-Wallis test 
was used for continuous variables and Chi-squared or Fisher’s exact test used for categorical 
variables as appropriate. A p-value <0.05 was considered statistically significant. Post hoc 
comparison tests were performed using Dunn test or Bonferroni correction as appropriate.
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7
Linear regression models: Logistic regression using forward, backward and bidirectional 
stepwise selection was employed using the glm function in R.
Gene expression predictors were selected by L1 (LASSO) sparse logistic regression using R 
package glmnet. The penalty parameter λ was optimised using 10-fold cross-validation. λ 
corresponding to the minimum mean cross-validated error was retained as final penalty 
parameter in the model. 
Predictive performance evaluation:  PThe predictive performance of the final prediction model 
was assessed by computing the area under the receiver operating characteristic curve (AUC), 
using both apparent and internal validation with 95% CI. Internal validation using a bootstrap 
method [16,17] (performed with R package boot version 1.3-18) was employed to correct for 
over-fitting, to generate unbiased optimism-adjusted estimates of the C statistic (AUC) with 
low absolute error. Bootstrap estimate of the AUC statistic was computed by random sampling 
with replacement 500 times to enable estimation of the optimism corrected AUC. 
RESULTS 
Patient demographics and clinical correlations 
200 PEAC patients were included, 128/200 (64%) patients were classified as RA1987 (RA 
1987+/RA2010+) and 72/200 (36%) as UA.  Of the UA patients, 25 were further classified as 
RA2010 (RA1987-/RA2010+) (25/200, 12.5%) and 47 remained as UA (RA1987-/RA2010-) 
(47/200, 23.5%) (Figure 1A). No significant difference in mean age, disease duration or ESR 
level between groups was demonstrated. However, the RA1987 group had significantly higher 
levels of CRP, TJC, SJC, DAS28, RF, ACPA and VAS and significantly higher numbers of 
patients sero positive for RF and ACPA compared to either the RA2010 or UA groups (Figure 
1B). SJC and ACPA titre were the only clinical parameters with significant differences between 
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8
the RA2010 and UA groups, indicating that in terms of clinical measures of disease activity 
these two groups are relatively homogenous. 
Synovial pathotypes distinguish clinical phenotypes regardless of disease duration
Synovial biopsies were obtained predominantly from small joints (81.5%) (Figure 2A). 
Patients with synovial tissue suitable for histological analysis (166/200) were segregated 
according to baseline synovial pathotype (Figure 2B) and differences in clinical parameters 
evaluated. We demonstrated significantly higher mean DAS28 within the lympho-myeloid 
compared to either the diffuse-myeloid or pauciimmune group (5.82 vs 4.93 vs 4.86, p<0.001). 
Mean CRP was also significantly higher in the lympho-myeloid and diffuse-myeloid vs 
pauciimmune groups (16.86 vs 15.52 vs 9.55, p<0.001) and a significantly higher number of 
patients were sero-positive for either RF (p=0.012) or ACPA (p=0.011) within the lympho-
myeloid group (Figure 2C).  To evaluate whether disease duration influenced prevalence of 
synovial pathotype, patients were stratified into four groups according to disease duration at 
baseline (1-3m, 4-6m, 7-9m and 10-12m) and frequency of synovial pathotype determined. No 
significant differences in synovial pathotype frequency at each time point was demonstrated 
(p=0.65) (Figure 2D). 
RA1987 patients display significantly higher levels of synovial immune cell infiltration 
compared to RA2010 and UA patients
Patients were segregated according to pathotype and further into RA1987, RA2010 and UA 
categories. A numerically higher proportion of patients within the RA1987 group were 
categorised as lympho-myeloid (vs diffuse-myeloid or pauciimmune) (43.5% vs 33% vs 
23.5%) (Figure 3A). We also demonstrated a significantly higher mean synovitis, CD3+ T cell, 
CD20 +B cell, CD138+ plasma cell and CD68+ SL/L macrophage score between the RA1987 
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group and both the RA2010 and UA groups (p<0.001) (Figure 3B). WInterestingly we saw no 
significant differences in synovitis score, mean CD3+T, CD20+B, CD68+ L or SL macrophage 
or CD138+ plasma cell number between the RA2010 and UA group (Figure 3B), indicating 
that these two groups are relatively homogenous in terms of tissue pathology. 
Synovial genes regulating B cell activation and function are significantly upregulated in 
RA1987 patients compared to the RA2010/UA groups. 
145/200 patients had RNA available for nanostring analysis (95/128 RA1987, 12/25 RA2010 
and 38/47 UA patients) and were analysed for differential gene expression (238 genes) between 
diagnostic groups.
Comparing RA1987 vs RA2010 groups we demonstrated a significant differential expression 
of 53 genes (Figure 3C).  In line with the histological analysis a number of differentially 
upregulated genes within the RA1987 cohort were involved in mediating B cell 
activation/function (e.g. CD79A, CD38, IGJ, CXCL13, IRF4, CCL19, CD38, TNFA, and IL6). 
When evaluating gene expression between the RA1987 and UA groups we found a similar 
trend with differential upregulation of a number of genes within the RA1987 cohort mediating 
B cell activation/function although only CXCL13 remained significant following correction for 
multiple comparisons (Figure 3D).  Conversely when evaluating gene expression between the 
RA2010 and UA cohorts only 7 genes appeared as significant with a preponderance of 
differentially upregulated genes within the RA2010 cohort mediating cartilage biology 
(COMP, DKK3, INHBA) and none remaining significant after correction for multiple 
comparisons (Figure 3E). 
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10
Classification as RA1987 criteria at disease onset predicts persistent disease at 12 months  
In 190/200 patients hadwith 12 month follow up data available, we examined whether baseline 
synovial pathotype was associated with disease evolution. 119/121 (99%) RA1987 patients and 
19/22 (90%) RA2010 had PD (Figure 4A). Within the UA cohort 11/47 (23%) had other 
diagnoses (Figure 4A). Of the remaining 36 patients, 26/36 (72.2%) had PD, and 10/36 (27.8%) 
SL. Of the UA patients with PD 4/26 (15.3%) progressed to fulfil 2010ACR/EULAR criteria 
RA at 12 months. Results demonstrated a significantly higher proportion of patients with SL 
disease in the UA group compared to the RA2010 or RA1987 groups and a significantly higher 
number of patients within the RA1987 group with PD (Figure 4B). When  we evaluatinged the 
effect of baseline pathotype we demonstrated aa numerically higher proportion of patients with 
a lympho-myeloid vs diffuse-myeloid or pauciimune pathotype (39% vs 32% vs 13%) with PD 
and a numerically higher number of patients with a diffuse-myeloid vs lympho-myeloid or 
pauciimmune pathotype (54% vs 18% vs 27%) with SL (Figure 4C). 
A baseline lympho-myeloid pathotype significantly associates with 12 month requirement 
for biologic therapy. 
Patients stratified according to diagnostic group or pathotype were further classified according 
to 12 month treatment requirement: i. symptomatic treatment, ii. csDMARDs or iii. 
biologics+/-csDMARDs. A significantly higher proportion of RA1987 patients required 
biologic compared with RA2010 and UA (27.82% vs 20.83% vs 10.63%) (p<0.001) (Figure 
5A) and importantly, lympho-myeloid (vs diffuse-myeloid or pauciimmune) pathotype 
significantly associated with 12 month requirement for biologic therapy when patients were 
classified as lympho-myeloid vs diffuse-myeloid or pauciimmune (57% vs 21% vs 21% 
p=0.02) (Figure 5B). 
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11
We then compared expression of the 238 genes in the Nanostring panel between patients 
requiring biologic therapy (n=34) or not (n=106) and found 119 differentially expressed genes. 
Patients requiring biologic therapy had, similarly to the RA1987 group, significantly higher 
differential upregulation of genes regulating B and T cell proliferation, differentiation and 
activation (e.g. TNFRSF13C, CD79A, CD2, CD3E and CD38), genes involved in matrix 
metallopeptidase production/regulation (e.g. MMP1 and TIMP1), genes involved in cytokine 
mediated cellular activation (TNFA, TRAF3IP3, IFNA1), and osteoclastogenesis inhibition 
(DEF6) (Figure 5C). Patients who did not require biologic therapy expressed some B and T 
cell regulation genes and B proliferation markers but mostly markers of fibroblast proliferation 
and cartilage turnover (Figure 5C). 
To determine whether disease duration also influenced outcome we segregated patients 
according to 12 month treatment (with biologic therapy or not) and further into quartiles of 
disease duration quartiles (Figure 5D) and, we demonstrated no significant differences between 
groups in terms of disease duration at diagnosis. Next, we segregated patients treated with 
biologic therapy (n=39) according to quartiles of disease duration and thenfurther into synovial 
pathotype.  We found no significant differences in patient number in each quartile (P=0.3) 
(Figure 5E). These results strongly suggest that synovial pathotype rather than disease duration 
influences 12 month treatment outcome. 
Synovial gene expression signatures enhance the performance of clinical prediction 
models for biologic requirement 
To determine whether baseline clinical and gene expression data could be combined into a 
model for predicting requirement for biologic therapy, we used 2 complementary approaches: 
a logistic regression model to identify the most predictive clinical covariates, and a penalized 
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method based on logistic regression with an L1 regularisation penalty (LASSO) to identify 
genes that improvinge the clinical model. 
9 baseline clinical covariates were considered as candidates in the regression model: disease 
duration, ESR, CRP, RF, ACPA, TJC, SJC, DAS28, and pathotype (two categories, lympho-
myeloid vs pauciimmune/diffuse-myeloid). Logistic regression models using backward 
forward and bidirectional stepwise selection resulted in selection of the same set of clinical 
covariates: DAS28, pathotype, CRP and TJC. The apparent predictive performance of the 
model evaluated by AUC was 0.78 (95% CI=0.70-0.87).
Genes were selected to improve the clinical model using logistic regression with an L1 
regularization penalty (LASSO) applied on the 4 clinical covariates selected by the previous 
logistic regression and the 119 genes identified as being significantly differentially expressed 
between the biologic and non-biologic groups. Models in which clinical predictors were 
penalised or subject to forced inclusion were compared. When all the predictors were penalised, 
11 predictors were retained in the final model and when the clinical covariates were not 
penalised, 13 predictors were retained in the final model (Figure 6A). In both the penalised and 
unpenalized clinical model the apparent prediction performance was improved (apparent 
AUC=0.89, 95% CI=0.83-0.95 and AUC=0.90, 95% CI=0.84-0.95) (Figure 6B). We 
additionally performed internal validation to correct the AUC performance measure for over-
fitting by calculating the optimism of the AUC for each model by boot-strapped sampling with 
replacement from the original dataset. The optimism corrected AUC was 0.75 for the pure 
clinical model and 0.81 for the clinical and gene model (LASSO) (Figure 6C and 6D) 
suggesting that including both clinical covariates and genes in the model results in an 
improvement of the predictive ability of the model. 
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DISCUSSION 
These results present a number of novel findings: firstly they strongly suggest that early 
inflammatory arthritis patients not fulfilling RA1987 criteria display similar clinical, synovial 
histological and molecular features irrespective of further classification according to RA2010 
or UA criteria. Secondly these data also suggest that a lympho-myeloid pathotype at disease 
onset predicts poor outcome with pati nts subsequently requiring biologic therapy irrespective 
of clinical classification, and finally that integration of histological and molecular signatures 
into a clinical prediction model enhances sensitivity/specificity for predicting whether patients 
will require biologic therapy. 
To the best of our knowledge these results emerge from the largest synovial tissue treatment-
naïve early arthritis cohort reported to date and support previous data from early RA cohorts 
suggesting that a synovial immune cell infiltrate characterised by a predominant infiltrate of B 
cells associates with more active disease [18] and sero-positivity for RF and ACPAPA [13] 
[10]. . The results in this cohort suggest that this effect also extends to patients within the UA 
cohort. The clinical similarities between RA2010+/RA1987- patients and those with UA has 
been reported previously [8] and the data presented herein provides a pathophysiological 
explanation for this with the demonstration of homogeneous synovial cellular and molecular 
signatures among the two groups.  The data show a lower percentage of patients requiring 
biologic therapy in RA2010+/RA1987- group, in line with the expectation that the 
ACR/EULAR 2010 criteria enable an earlier diagnosis and thus efficacious treatment. 
However, it is also possible that this group has a milder pathology from the beginning. 
Although synovial pathotypes per se do not appear to distinguish between patients at risk of 
developing PD rather than SL disease, this is not surprising given the early and treat-to-target 
approach pursued in the study rather than observing untreated natural disease evolution. 
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However when applying 12 month biologic requirement as a prognostic outcome we 
demonstrated that patients with a lympho-myeloid pathotype with a dense synovial infiltrate 
enriched in B cells and significant upregulation of T/B cell genes at disease onset predicted 
requirement for subsequent biologic therapy and critically that this was independent of disease 
duration. These results are consistent with recently published data in early RA which reports 
that thea lympho-myeloid pathotype is associateding with both highly agressivective disease 
and worse radiographic outcomes [10]. The current study presented reinforces these findings 
demonstrating that, at 12-months follow-up, a significantly higher proportion of patients 
classified as lympho-myeloid pathotype required biologic therapy. The study  through 
application of an alternative prognostic outcome (requirement for biologic therapy) but 
alsoThese results calls into question the current dogma surrounding “an early window of 
opportunity” for all patients with RA [19–21], suggesting that pathotype rather than simply 
disease duration influences outcome and that intensive therapeutic regimens should be targeted 
to poor prognostic pathotypes.  This notion is supported 
 by the demonstration that the integration of synovial histological and molecular markers into 
a clinical prediction model for biologics use improves sensitivity/specificity from from 78.8% 
to 89-90% independently from disease duration.
The fact that the majority of biopsies were performed on small joints may also explain the 
differences Discrepancy with previously reported data suggesting that synovial heterogeneity 
does not relate to clinical phenotypes [9], maybe explained by the fact that in our study the 
majority of biopsies were performed on small joints while inas that cohort arthroscopic biopsy  
was restricted to patients with mainly large joint involvement risking significantand, thus, a 
potential selection bias [22]. Additionally, the paired histological and molecular data in the 
largest pathobiological biopsy-driven early arthritis cohort (200 patients) reported to date 
ensured internal validation and high classification accuracy. 
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Our study does have limitations however, for example the real-life nature of the study did not 
permit the true evaluation of the natural history of the disease or outcome, as no patients were 
left untreated and therapy was not actively withdrawn. Also a treat to target approach, treatment 
escalation and initiation of biologic therapy was determined by treating physicians according 
to NICE guidelines rather than study protocol. 
Within these limitations, our results are robust and suggest that the introduction of the new 
RA2010 classification criteria brings additional clinical and biological heterogeneity into early 
patient classification compared to the 1987 criteria with limited ability of RA2010 criteria alone 
to predict poor outcome. The demonstration that the integration of synovial pathobiological 
markers into clinical algorithms predicting poor outcome (requirement for biologic therapy) 
independent of disease duration suggests that the “window of opportunity” is wider than 6 
months and early stratification of biologic therapies according to poor prognostic synovial 
pathobiological subtypes at disease onset may improve the outcome of these patients. 
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Figure Legends
Figure 1. Baseline Patient Demographics. 
A. Baseline classification of patients. 200 patients were classified into RA1987 vs 
undifferentiated arthritis (UA). RA 2010 ACR/EULAR Criteria was then applied to UA 
patients. Final 3 groups obtained showed 47 patients UA (RA 1987-/RA2010-), RA 
2010 (RA1987-/RA2010+), RA 1987 (RA1987+/RA2010+). 
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B. Demographics according to classification criteria. Data are presented as mean (SD, 
standard deviation) for continue variables and frequency and percentages for 
categorical variables. Baseline characteristics between the 3 groups were compared 
using Kruskal-Wallis or Fisher’s exact test as appropriate. For post hoc comparison, 
Dunn tests were run and p-value from pairwise comparison reported in the last 3 
columns of the table. ESR: Erythrocyte sedimentation rate ; CRP: C-reactive protein; 
28TJC: 28 tender joint count; 28SJC: 28 swollen joint count; DAS28: Disease Activity 
Score 28 joints; RF titre: Rheumatoid factor titre (IU/ml); ACPA Titre: Anti-
citrullinated protein antibody titre (IU/L); RF +ve: rheumatoid factor serum positive 
(>15IU/L); ACPA +ve: Anti-citrullinated protein antibody (>20IU/L).
Figure 2. Patient demographics and disease activity: comparison between pathotypes. 
A. Number of biopsy procedures per joint  MCP (Metacarpophalangeal), MTP 
(Metatarsophalangeal), PIP (Proximal Inter phalangeal). 
B. Representative images of synovial pathotypes. H&E: Haematoxylin & Eosin. 
Sections underwent immunohistochemical staining and semi-quantitative scoring (0-4) 
to determine the degree of CD20+ B cells, CD3+ T cells, CD68+ lining (l) and sublining 
(sl) macrophage and CD138+ plasma cell infiltration. Sections were categorised into 
three pathotypes: (i) Pauci-iumne (CD68 SL<2 and or CD3, CD20, CD138<1), (ii) 
Diffuse-Myeloid: (CD68SL>2, CD20<1 and or CD3>1) and (iii) Lympho-Myeloid: 
(grade 2-3 CD20+ aggregates, CD20>2). Arrow heads  indicate positive stain cells. 
Empty arrows indicate B cell aggregates.
C. Demographic Analysis by Pathotype. Data are presented as mean and standard 
deviation (SD) for numerical variables and frequency and percentage for categorical 
variables. Baseline characteristics between the 3 pathotypes were compared using a 
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Kruskall-Wallis test and Fisher-test (RF and ACPA positivity) as appropriate. Post hoc 
analysis for significant differences using Dunn test for multiple comparison. A P-value 
of <0.05 was considered statistically significant. 
D. Pathotype according to disease duration (months) at diagnosis. Absolute values (N) 
and percentage. A P-value of <0.05 was considered statistically significant. 
Figure 3. Variation in synovial pathobiology according to clinical classification of 
patients. 
A. Baseline clinical classification compared with pathotype. Baseline subgroups (RA 
1987, RA2010 and UA) were compared with pathotype. Fisher test used for analysis. 
B. Immune cell infiltration for each clinical subgroup. Kruskal-Wallis test for 
comparison between 3 groups. Post hoc analysis for significant differences using Dunn 
test for multiple comparison.
C. (C-E) Gene expression analysis for comparison between subgroups. T-test for 
comparison and Volcano plot for representative image. Positive values represent 
upregulation and negative values downregulation. Green circles above green horizontal 
line represents non-corrected for multiple analysis expressed genes between groups. 
Red circles above red line represents corrected p-values (Benjamini-Hochberg method) 
for multiple analysis. (C) Volcano plot RA 1987 vs RA 2010: Difference in gene 
expression between patient fulfilling RA 1987 ACR criteria and RA 2010 
ACR/EULAR Criteria. (D) Volcano plot RA 1987 vs UA: Difference in gene 
expression between patient fulfilling RA 1987 ACR criteria and Undifferentiated 
Arthritis. (E) Volcano plot RA 2010 vs UA: differences in gene expression between 
patient fulfilling RA 2010 ACR/EULAR criteria and UA.  
Figure 4. Disease evolution. 
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A. Patient classification after 12 months follow up. Disease outcome after 12 months 
of follow up for each of the initial baseline subgroups (RA1987/RA2010/UA). 
Disease evolution classified as self-limiting or persistent disease. Other diagnosis as 
described for those who were re-classified after 1 year form UA cohort. 
B. Disease evolution by subgroups. Disease evolution was compared with Baseline 
subgroups (RA 1987, RA2010 and UA). Fisher test used for analysis. 
C. Disease evolution by pathotype. Disease evolution was compared with pathotype 
(Pauci-imune vs Diffuse-Myeloid vs Lympho-Myeloid. Fisher test used for analysis. 
A P-value of <0.05 was considered statistically significant. 
Figure 5. 
A. Comparison between diagnostic subgroups and treatment outcome at 12month 
follow up. Treatment required was divided in 3 groups: (i) No treatment; (ii) 
csDMARDs only,  (iii) csDMARDs +/- Biologics. Fisher test for analysis. 
B. Comparison between pathotype and treatment outcome at 12 months. 
C. Gene expression analysis, represented in a Volcano plot comparison between patient 
requiring Biologics vs non-biologic group. T-test comparison for gene difference 
expression between groups. Positive values represents upregulation and negative values 
downregulation. An adjusted (Benjamini-Hochberg correction for multiple analysis) P-
value of <0.01 was considered statistically significant, represented as dots above red 
line. Green dots above green line for gene expression significance when no correction 
applied for multiple analysis (P value <0.05). D. Treatment outcome according to 
baseline disease duration. Fisher test for analysis. E. Pathotype according to 
baseline disease duration for Biologic patient cohort. Fisher test for analysis. A P-
value of <0.05 was considered statistically significant unless otherwise stated.
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Figure 6. Prediction model. 
A-B Identification of clinical and gene expression features predictive of biologic 
therapy use at 1 year. Logistic regression, coupled with backward and stepwise model 
selection was applied to baseline clinical parameters against a dependent variable of 
Biologic therapy use or not at 12 months to select which clinical covariate contributed 
the most to the prediction. Selected covariates (119 genes+4 clinical covariates) were 
entered simultaneously into a logistic model with an L1 regularization penalty 
(LASSO) in order to determine the optimal sparse prediction model. A similar 
predictive performance of the model when clinical was seen when results were 
penalized (blue dashed line, figure 6A) than when they were not penalized (red dotted 
line, figure 6A) with a slightly different set of selected covariates (Figure 6B). Figure 
6B shows the non-zero weights associated with the final variables selected by the 
LASSO regression. The grey spaces represent the variables that were not selected by 
the model.
C-D Lambda training curve from the final glmnet fitted model. The red dots
represent mean binomial deviance using 10-fold cross-validation. The error bars 
represent standard error of binomial deviance. The vertical dotted lines indicate 
minimum binomial deviance (λmin) and a more regularized model for which the 
binomial deviance error is within one standard error of the minimum binomial deviance 
(λ1se). λmin was selected, corresponding to 11 non-zero coefficients in the final model 
for the LASSO where clinical were penalized (Figure 6C) and 13 non-zero coefficients 
in the final model for the LASSO where clinical were not penalized (Figure 6D).
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Key messages: 
What is already known about this subject?
The introduction of ACR/EULAR RA classification criteria have impacted positively on early
diagnosis and treatment RA leading to better outcomes.  By the same token, broader criteria 
have led to the inclusion of patients with milder and more heterogenous disease. This, together 
with the inability to precisely predict disease prognosis and treatment response at the individual 
patent levels, emphasise the need to identify patients at risk of accelerated structural damage 
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progression and fast-track aggressive/biologic therapies to patients with poor prognosis. 
What does this study add?
This study analyses the largest biopsy-driven early inflammatory arthritis cohort to date (200 
patients) and, through a detailed synovial cellular and molecular characterization refines 
ACR/EULAR disease classification. In addition, the study identifies synovial pathobiological 
markers associated with with the lympho-myeloid pathotype and the requirement of biologic 
therapy requirement at 12 months, reinforcing recently published data the indicates that these 
patients are affected by highly agressive disease and worse radiographic outcome. Notably, 
these findings are independent from the time of diagnosis within the first 12 months of 
symptoms initiation, suggesting that the so called “window of opportunity” is wider than 6 
months and early stratification of biologic therapies according to poor prognostic synovial 
pathobiological subtypes at disease onset may improve the outcome of these patients. The 
integration of such synovial pathobiological markers into a logistic regression model improves 
the prediction accuracy from 78.8% (clinical) to 89-90% (clinical +  molecular) and enables 
the identification at disease onset of patients who subsequently require biologic therapy. Thus, 
this study provides support to the notion that biologic therapies should be started early in 
patients with poor prognosis.  
How might this impact on clinical practice or future developments?
The identification at disease onset of patients who are unlikely to respond to csDMARDs, 
remains a major unmet need. The capacity to refine early clinical classification criteria through 
application of synovial pathobiological markers and the ability to identify patients who 
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subsequently require biologic therapy at disease onset offers the opportunity to stratify 
therapeutic intervention to the patients most in need. This present study adds weight to the need 
to change current therapeutic algorithms and start biologic therapies at disease onset in patients 
with poor prognosis.  This is likely to have a major impact on disease control/remission and 
long-term disability, as notionally supported by numerous early intervention studies using 
biologic therapies. 
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We thank the reviewer for his/her helpful comment and have replied to the specific point 
below:
Reviewer: 2 
Comments to the Author 
In the revised version of the paper from Lliso-Ribera et al.  the authors have made minor 
edits to strengthen their main message. 
The importance of the paper is unquestionable. However, the authors should point out 
the additional benefits of this paper as compared to their most recent paper published by 
Humby et al., (in particular Figure 5). 
R: We agree with the reviewer that it is important to point out the additional benefits of this 
paper as compared to our most recent paper published (Humby et al. ARD 2019). As per the 
reviewer’s specific reference to Figure 5, this shows four important novel aspects compared 
to our above previous publication: (i) the requirement for bDMARD is significantly greater 
for early RA when categorised as RA 1987 + / RA 2010 + (27.82%) compared to RA 1987 - / 
RA 2010 + (20,83%) versus UA (10,63%): p<0.001; (ii) the requirement for bDMARD is 
significantly greater for patients displaying the lympho-myeloid pathotype versus diffuse-
myeloid versus pauciimmune: p<0.02; (iii) the above findings are independent from the time 
of diagnosis within the first 12 months of symptoms initiation, suggesting that the so called 
“window of opportunity” is wider than 6 months and early stratification of biologic 
therapies according to poor prognostic synovial pathobiological subtypes at disease onset 
may improve the outcome of these patients; (iv) it reports the identification of genes that 
improve on clinical prediction models on biologic requirement at 12 months. 
The above 4 points have been now further emphasised throughout the manuscript and also 
we have modified the discussion accordingly, which now reads (page 13-14)
“Although synovial pathotypes per se do not appear to distinguish between patients at risk 
of developing PD rather than SL disease, this is not surprising given the early and treat-to-
target approach pursued in the study rather than observing untreated natural disease 
evolution. However, when applying 12 month biologic requirement as a prognostic outcome 
we demonstrated that patients with a lympho-myeloid pathotype with a dense synovial 
infiltrate enriched in B cells and significant upregulation of T/B cell genes at disease onset 
predicted requirement for subsequent biologic therapy and critically that this was 
independent of disease duration. These results are consistent with recently published data in 
early RA which reports that the lympho-myeloid pathotype is associated with highly 
aggressive disease and worse radiographic outcome [10].  The current study reinforces these 
findings demonstrating that, at 12-months follow-up, a significantly higher proportion of 
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patients classified as lympho-myeloid pathotype required biologic therapy. The study also calls 
into question the current dogma surrounding “an early window of opportunity” for all 
patients with RA [18–20], suggesting that pathotype rather than simply disease duration 
influences outcome and that intensive therapeutic regimens should be targeted to poor 
prognostic pathotypes.  This notion is supported by the demonstration that the integration 
of synovial histological and molecular markers into a clinical prediction model for biologics 
use improves sensitivity/specificity.” 
Moreover, we have emphasised the additional benefits of this paper compared to our above 
previous publication in the Key messages: What does this study add? Page 24 and 25.
Due to the insertion additional text we have also made minor edits throughout the 
manuscript to remain as close as possible to the 3000-word count (now 3031), which we 
hope is acceptable. 
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N 200 RA 1987 
(RA 1987 + / 
RA 2010 +)
N 128
RA 2010
(RA 1987 - / 
RA 2010 +)
N 25
UA
(RA1987 - / 
RA2010-)
N 47
p-value p-value
(post-hoc)
RA 1987-
UA
p-value
(post-hoc)
RA1987-
RA2010
p-value
(post-hoc)
RA2010-
UA
Age (years). Mean (SD) 52.64 (16.02) 52.25 (12.54) 52.76 (15.33) 0.98
Disease duration (months). Mean (SD) 5.64 (4.48) 10.47 (25.28) 6.11 (3.51) 0.91
ESR. Mean (SD) 39.05 (19.69) 30.64 (30.06) 10.63 (21.51) 0.56
CRP. Mean (SD) 17.82 (13.89) 14.6 (20.36) 7.21 (12.35) 0.03 * <0.001 * 0.12 0.071
28 TJC. Mean (SD) 11.98 (7.29) 6.88 (5.72) 6.80 (6.79) <0.001 * <0.001 * 0.0012 * 0.74
28 SJC. Mean (SD) 7.68 (5.62) 5.68 (4.91) 3.10 (2.82) <0.001 * <0.001 * 0.042 * 0.031 *
Das 28. Mean (SD) 5.76 (1.35) 4.73 (1.56) 4.001 (1.51) <0.001 * <0.001 * 0.002 * 0.13
Vas global disease activity. Mean (SD) 64.82 (24.80) 45.36 (28.78) 34.55 (29.27) <0.001 * <0.001 * 0.0043 * 0.17
RF titre. Mean (SD) 25.53 (22.49) 2.68 (2.95) 1.27  (1.42) <0.001 * <0.001 * <0.001 * 0.21
ACPA titre. Mean (SD) 26.16 (18.42) 75.24 (175.40) 1.68 (10.56) <0.001 * <0.001 * <0.001 * 0.01 *
RF +ve. N (%) 84 (65%) 7 (28%) 1 (2%) <0.001 *
ACPA +ve. N (%) 87 (68%) 6 (24%) 2 (4%) <0.001 *
A
B
Figure 1
Early inflammatory arthritis treatment naïve patients cohort
(<12m symptoms)
N=200 patients
1987 ACR Classification Criteria
Undifferentiated Arthritis
72 patients
Rheumatoid Arthritis
(1987 ACR Criteria)
128 patients
2010 ACR/EULAR Classification Criteria
Undifferentiated Arthritis
UA
(RA 1987 - /  RA 2010 -)
47 patients
Rheumatoid Arthritis 2010
RA 2010
(RA 1987 - / RA 2010 +)
25 patients
Rheumatoid Arthritis 1987
RA1987 
(RA 1987 + / RA 2010 +)
128 patients
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Figure 2
C
N 166 Pauci-
immune  
N 47 
Diffuse-
Myeloid  
N 57 
Lympho-
Myeloid
N 62 
P value P-value
(post-hoc)
Lymphoid-M
vs
Pauci-immune
P value
(post-hoc)
Lymphoid-M
vs
Diff-Myeloid
P value
(post-hoc)
Diff-Myeloid
Vs
Pauci-immune
Age (years). Mean (SD) 54.93 (13.37) 52.64 (17.84) 51.90 (16.11) 0.51
D. Duration (m). Mean (SD) 9.21 (4.90) 9.30 (4.03) 9.54 (4.37) 0.98
ESR. Mean (SD) 33.04 (21.68) 28.19 (18.49) 36.96 (19.48) 0.12
CRP. Mean (SD) 9.55 ()13.45) 15.52 (14.68) 16.86 (12.96) <0.001 * <0.001 * 0.06 0.013 *
28 TJC Mean (SD) 10.38 (8.08) 8.70 (6.45) 11.22 (7.47) 0.09
28 SJC. Mean (SD) 5.70 (5.38) 5.96 (4.93) 7.75 (5.73) 0.054
DAS 28. Mean (SD) 4.86 (1.65) 4.93 (1.49) 5.82 (1.55) <0.001 * 0.0012 * 0.002* 1
VAS. Mean (SD) 50.29 (26.87) 53.47 (31.33) 61.32 (27.94) 0.08
RF +ve. N (%) 17 (64%) 27 (53%) 40 (65%) 0.012 *
ACPA +ve. N (%) 15 (32%) 27 (47%) 43 (70%) 0.011 *
RF titre. Mean (SD) 10.15 (15.40) 20.94 (23.95) 23.43 (22.74) 0.004 * 0.003 * 0.47 0.04 *
ACPA titre. Mean (SD) 16.16 (28.40) 19.67 (24.31) 43.79 (104.1) 0.002 * 0.007 * 0.06 0.29
130
26
4
3
35
2
0 50 100 150
Wrist
MCP
MTP
PIP
Knee
Elbow
200 patients
A B
N 166 1-3m 
N=54
N (%)
4-6m
N=53
N (%)
7-9m
N=37
N (%)
10-12m
N=22
N (%)
P value
Pauci-immune 19 (34.5%) 22 (38%) 8 (28%) 8 (28.5%)
0.65Diffuse-Myeloid 22 (40%) 17 (28%) 10 (31%) 5 (18%)
Lympho-Myeloid 13 (23.5%) 14 (23%) 9 (28%) 9 (32%)
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N 166 RA 1987 
(RA 1987 + / 
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